2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-03-09 |
|
2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-03-09 ±³À°ÁÖÁ¦ : 2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇÑ°©»ó¼±ÇÐȸ À̸ÞÀÏ : office@thyroid.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, º´¸®°ú, ÇÙÀÇÇаú Âü¼®¿¹»óÀÎ : 350¸í Áö¿ª : ´ëÀü±¤¿ª½Ã ¼¼ºÎ¼ö°·á : 120,000¿ø ºñ°í " 1. Àü¹®ÀÇ/ÀϹÝÀÇ 1) Æò»ýȸ¿ø ¹× Á¤È¸¿ø(¿¬È¸ºñ ³³ºÎÀÚ) »çÀüµî·Ï 90,000¿ø, ÇöÀåµî·Ï 110,000¿ø, 2) ºñȸ¿ø »çÀüµî·Ï 100,000¿ø, ÇöÀåµî·Ï 120,000¿ø 2. Àü°øÀÇ/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/°£È£»ç/±âÃÊÀÇÇÐÀÚ 1) Æò»ýȸ¿ø ¹× Á¤È¸¿ø(¿¬È¸ºñ ³³ºÎÀÚ) »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø, 2) ºñȸ¿ø »çÀüµî·Ï 70,000¿ø, ÇöÀåµî·Ï 90,000¿ø 3. ¸¸65¼¼ ÀÌ»óÀÎ Æò»ýȸ¿ø, Çкλý ¹× ÀÇÀü¿ø Çлý : ¹«·á"
±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 08:30~08:50 Clinical risk factors and risk stratification À̵¿±Ù(µ¿¾ÆÀÇ´ë À̺ñÀÎÈÄ°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 08:50~09:10 Imaging- based diagnosis and risk stratification À̹ΰæ(°¡Å縯ÀÇ´ë ¿µ»óÀÇÇаú) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 09:10~09:30 Interventional management of recurrent thyroid cancer ¹éÁ¤È¯(¿ï»êÀÇ´ë ¿µ»óÀÇÇаú) Åä·Ð 03¿ù 09ÀÏ 201È£ 09:30~09:40 Discussion ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 09:40~10:00 Recent results from the MAeSTro Study compared to prospective cohort studies in other countries ¹®ÀçÈÆ(¼¿ïÀÇ´ë ³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 10:00~10:20 Protocols of guidelines and prospective studies on AS of low risk PTC ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ ³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 10:20~10:40 Standardized imaging for thyroid ultrasound in AS of low risk thyroid cancer: KSThR consensus statement ÀÌÁö¿¹(¼¿ïÀÇ´ë ¿µ»óÀÇÇаú) Åä·Ð 03¿ù 09ÀÏ 201È£ 10:40~10:50 Discussion ( ) ÈÞ½Ä 03¿ù 09ÀÏ 201È£ 10:50~11:10 Coffee Break ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 11:10~12:10 Genome editing and medicine ±èÇü¹ü(¿¬¼¼ÀÇ´ë ¾à¸®Çб³½Ç) ±âŸ 03¿ù 09ÀÏ 201È£ 12:10~12:30 ÃÑȸ ( ) ½Ä»ç 03¿ù 09ÀÏ 201È£ 12:30~13:20 Lunch ( ) Åä·Ð 03¿ù 09ÀÏ 201È£ 13:20~14:20 ÆгÎÅäÀÇ ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 14:20~15:00 How to minimize the complications of the thyroid surgery ÀÌ°´ë(°í½ÅÀÇ´ë À̺ñÀÎÈÄ°ú) ÈÞ½Ä 03¿ù 09ÀÏ 201È£ 15:00~15:20 Coffee Break ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 15:20~15:50 Organoids in thyroid gland À¯¹ÎÈñ(¾ÈÀü¼ºÆò°¡¿¬±¸¼Ò) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 15:50~16:20 Epigenomic analysis in thyroid cancer ±è¶ô±Õ(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í°øÇаú) Åä·Ð 03¿ù 09ÀÏ 201È£ 16:20~16:30 Discussion ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 16:30~16:55 2024³â ´ëÇÑ°©»ó¼±ÇÐȸ °©»ó¼±¾Ï Áø·á±Ç°í¾È ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ ³»°ú) Åä·Ð 03¿ù 09ÀÏ 201È£ 16:55~17:20 ÆгÎÅäÀÇ ÀÓµ¿ÁØ ³ªµ¿±Ô ±èÁ¤ÇÑ ±¸º»¼® Á¤Âù±Ç ÀÌ»ó¿ì(°¡Å縯ÀÇ´ë ³»°ú °¸ª¾Æ»êº´¿ø ¿µ»óÀÇÇаú ¼º±Õ°üÀÇ´ë ¿Ü°ú Ãæ³²ÀÇ´ë À̺ñÀÎÈÄ°ú °¡Å縯ÀÇ´ë º´¸®°ú °æºÏÀÇ´ë ÇÙÀÇÇаú) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 17:20~17:30 ÀúÀ§Ç豺 °©»ó¼±¾ÏÀÇ Ä¡·á ¹æħ¿¡ ´ëÇÑ KTA ¼³¹®°á°ú ±è¹ÎÁÖ(¼¿ïÀÇ´ë ³»°ú) Åä·Ð 03¿ù 09ÀÏ 201È£ 17:30~17:40 Discussion ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 201È£ 17:40~17:50 °©»ó¼±±â´ÉÇ×ÁøÁõÀÇ ¹æ»ç¼º¿ä¿ÀµåÄ¡·á ±Ç°í¾È ±è°æÁø(°í·ÁÀÇ´ë ³»°ú) Åä·Ð 03¿ù 09ÀÏ 201È£ 17:50~18:00 Discussion ( ) ±âŸ 03¿ù 09ÀÏ 201È£ 18:00~18:10 ½Ã»ó½Ä ¹× Closing Remark ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 08:30~08:40 [±¸¿¬¹ßÇ¥] Ultrasound-Guided Thrombin Injection for the treatment of choice for iatrogenic thyroid pseudoaneurysm "ÇÔÅÂÇõ (¼¿ï´ëÇб³º´¿ø ¿µ»óÀÇÇаú)" ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 08:40~08:50 [±¸¿¬¹ßÇ¥] Cost-effectiveness of diagnosis by ultrasound for asymptomatic thyroid cancer in South Korea "Á¤È£Áß (°³²¼¼ºê¶õ½ºº´¿ø ¿Ü°ú)" ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 08:50~09:00 [±¸¿¬¹ßÇ¥] Intraoperative Neuromonitoring During Thyroidectomy Does Not Decrease Vocal Cord Palsy Risk, but Cumulative Experience May "¿À¹®¿µ (¼¿ïƯº°½Ãº¸¶ó¸Åº´¿ø ¿Ü°ú)" ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 09:00~09:10 [±¸¿¬¹ßÇ¥] Association between M2 macrophage infiltrations and radioactive iodine sensitivity in thyroid cancer "ÀÌÀÚ°æ (ºÐ´ç¼¿ï´ëÇб³º´¿ø ¿Ü°ú)" ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 09:10~09:20 [±¸¿¬¹ßÇ¥] Continuous intraoperative nerve monitoring in thyroidectomy using automatic periodic stimulation: preliminary case series "¹èÁØÇü (ºÐ´ç¼¿ï´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú)" ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 09:20~09:30 [±¸¿¬¹ßÇ¥] ´ëÇѵΰæºÎ¿Ü°úÇÐȸ °©»ó¼±¾Ï °ËÁø ¹× Ä¡·á µ¿Çâ ´ëȸ¿ø Á¶»ç º¸°í "±èÁö¿ø (ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ À̺ñÀÎÈÄ°ú)" ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 09:40~10:00 °©»ó¼± ¼ö¼úÀÇ Á¾·ù¿Í ÀÔ¿øȯÀÚ ÄɾîÀÇ ÁÖÀÇÁ¡ ÇãÁØ(¿¬¼¼ÀÇ´ë ¿Ü°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 10:00~10:20 °©»ó¼± ¾àÁ¦ÀÇ Ã³¹æ ¹× º¹¿ë ¿ä·É ¼ÛÀÇ¿¬(°í·ÁÀÇ´ë ³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 10:20~10:40 ¹æ»ç¼º ¿ä¿Àµå Ä¡·á ÈÄ È¯ÀÚ ÄÉ¾î ¹Ú¼ÒÇö(±¹¸³¾Ï¼¾ÅÍ ÇÙÀÇÇаú) Åä·Ð 03¿ù 09ÀÏ 204,5È£ 10:40~10:50 Discussion ( ) ÈÞ½Ä 03¿ù 09ÀÏ 204,5È£ 10:50~11:10 Coffee Break ( ) ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 15:20~15:40 Pros for T3 + T4 combination À̽ÃÈÆ(°¡ÃµÀÇ´ë ³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 15:40~16:00 Cons for T3 + T4 combination ±èº¸Çö(ºÎ»êÀÇ´ë ³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ 204,5È£ 16:00~16:20 A Comprehensive overveiw of recent guidelines ±è´ÙÇÔ(¿¬¼¼ÀÇ´ë ³»°ú) Åä·Ð 03¿ù 09ÀÏ 204,5È£ 16:20~16:30 Discussion ( )
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|